Reported results
- The Company reported a net loss of $31.1 million, or $0.29 per common share, for the third quarter of 2026.
- Research and development expenses were $25.9 million for the third quarter of 2026.
- General and administrative expenses were $6.5 million in the third quarter of 2026.
- As of September 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $128.7 million.
- The Company reported a net loss for the first nine months of 2026 of $93.5 million, or $0.90 per common share.
Guidance
- The Company projects its cash runway into late Q2 2027.
- BLA Submission Acceptance: Early 2027
- Open Label Study Safety Update: Q1 2027
- U.S. Approval: Mid-2027
- Obtaining & Monetizing the Rare Pediatric Disease Priority Review Voucher: Mid-2027, if approved
- U.S. Launch: Targeting Q3 2027 launch, if approved
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
